Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Rambam Health Care Campus.
Recruitment status was  Not yet recruiting
Information provided by:
Rambam Health Care Campus Identifier:
First received: September 14, 2005
Last updated: February 22, 2006
Last verified: September 2005

This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan.

This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.

Condition Intervention Phase
Drug: candesartan
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Educational/Counseling/Training
Official Title: ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • ACE and ACE2 activities in monocytes

Estimated Enrollment: 20

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent
  • Non-smokers
  • Type II DM diagnosed patients
  • Blood pressure < 135/90
  • Serum HbA1C > 7%
  • Serum creatinine < 1mg%
  • Urine microalbumin < 300 mg/day
  • Body mass index (BMI) < 35 kg/m2

Exclusion Criteria:

  • Insulin-dependent diabetic patients
  • Patient with persistent microalbuminuria
  • Patient with history of severe hypertension
  • Congestive heart failure
  • Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications.
  • Patient with major hepatic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00192803

Contact: Shlomo Keidar, MD 97248542518

Internal Ward "A", Rambam Medical Center Not yet recruiting
Haifa, Israel
Contact: Ayelet Raz, MD    972-4-8543072      
Sub-Investigator: Ayelet Raz, MD         
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Shlomo Keidar, MD Rambam Health Care Campus
  More Information Identifier: NCT00192803     History of Changes
Other Study ID Numbers: ACE2.CTIL 
Study First Received: September 14, 2005
Last Updated: February 22, 2006
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Rambam Health Care Campus:
NIDDM patients

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Antihypertensive Agents processed this record on May 26, 2016